Marco Hofmann

biologist, scientist, drug-hunter, oncology research

[Norbert Kraut @norbertkraut1]

Out now in @NatureCancer. Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to @MDAndersonNews, @timheff5 and team and congrats to the @Boehringer #KRAS team
https://t.co/phMjUzuHwL

[Norbert Kraut @norbertkraut1]

Thanks for including our paper published in
@CD_AACR
describing BI-3406, a potent and selective SOS1-KRAS interaction inhibitor.
https://t.co/s46WdvY3cm
@MarcoHHofmann
@D_B_McConnell
@Real_Dr_Kessler
@gerlach_d
@timheff5
#KRAS #AACR23

[Elizabeth McKenna @ElizSMcKenna]

#AACR23: For more on Beating #KRAS, don't miss this @CD_AACR review - Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants @MarcoHHofmann @gerlach_d @Sandra_Misale @norbertkraut1 https://t.co/zNLgkXrLBw

[Anna Obenauf @obenaufa]

Looking forward to an exciting program of the @EACRnews @Boehringer virtual conference
"Drugging and Regulating the MAP Kinase Pathway" co-organized with #ReneBernards @msmelanoma @MarcoHHofmann @Ralph_A_N
So many developments in this field and challenges we need to tackle!

[Molecular Oncology @MolOncology]

The first session of #eacrMAPKpathway is underway with @MarcoHHofmann @Boehringer introducing the interplay between inhibitors of SOS1 and KRAS

Combination with SOS1i overcomes induced resistance to KRAS-G12Ci

Does the upregulation of MRAS and RASGRP1 help explain resistance?

[venu☘️ @itsvenu_]

Check out our work on KRAS G12Ci + KRAS::SOS1i as a viable combination therapy to address KRAS G12Ci resistance. This work is the result of @Boehringer & @MDAndersonNews partnership.

#KRAS @gerlach_d @norbertkraut1 @MarcoHHofmann @KRASKickers

https://t.co/wwZfqTNiJn

[Daniel Gerlach @gerlach_d]

Combined KRAS G12Ci + KRAS::SOS1i inhibition overcomes acquired resistance in Adagrasib-resistance CRC models - new pre-print from the @Boehringer and @MDAndersonNews partnership by @itsvenu_, Hengyu Lu and @MarcoHHofmann #KRAS #BI3406 #First4Patients

https://t.co/WQ5pPA3n9b

[Anirban Maitra @Aiims1742]

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by @norbertkraut1 @Sandra_Misale @gerlach_d @MarcoHHofmann in @CD_AACR - #OpenAccess & worth reading!
https://t.co/0OXb2L78F3

[Daniel Gerlach @gerlach_d]

🗓️Virtual conference upcoming "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway" with a great line-up of speakers. Join on February 21-22, 2023 to get the latest updates in the field. Registration: https://t.co/wM7jQkacI3 @EACRnews @Boehringer

[Boehringer Ingelheim @Boehringer]

#RESEARCHERS: Our scientists foresee a concept of two potential future classes of #KRAS medicines - just published in @CD_AACR! 👉 https://t.co/AhNkxMYNl8

[Cancer Discovery @CD_AACR]

Just published: A Review on Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
https://t.co/QyAfwBiqYs
@norbertkraut1, @MarcoHHofmann, @gerlach_d, @Sandra_Misale, and Mark Petronczki

[Daniel Gerlach @gerlach_d]

📢Expanding the reach of precision🎯oncology by drugging all #KRAS mutants - our new review is out in
@CD_AACR https://t.co/vVkeveBc1r. Thanks to @MarcoHHofmann, @gerlach_d, @Sandra_Misale, Mark, and @norbertkraut1 #First4Patients #TakingCancerOn

[Norbert Kraut @norbertkraut1]

Excited to partner with Amgen, combining our clinical-stage SOS1::pan-KRAS inhibitor with sotorasib, the first US FDA approved KRAS-G12C inhibitor. #KRAS #first4patients

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️MD Anderson & Boehringer Ingelheim have expanded their joint Virtual Research & Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer @timheff5 #AACR21
@MDAndersonNews @boehringerus
https://t.co/UcBQbhgkQH

[Norbert Kraut @norbertkraut1]

Great collaboration with @timheff5 and team at @MDAndersonNews
Check out our joint presentations #AACR21 #KRAS #first4patients @D_B_McConnell
@MarcoHHofmann
@gerlach_d
@DraettaG
@joemarszalek

[Dirk Kessler @Real_Dr_Kessler]

So exited to share our latest paper on SOS1 and the Discovery of BI-3406. Switching from a fluorine to a chlorine makes an inhibitor out of an activator. One Atom Makes All the Difference! @D_B_McConnell @ACSBioMed https://t.co/g1xZgXTw4k

[Daniel Gerlach @gerlach_d]

Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published & formatted in the January 2021 issue of Cancer Discovery @CD_AACR - https://t.co/JtwNf5wMXS @MarcoHHofmann @norbertkraut1 @timheff5 @Boehringer

[Boehringer Ingelheim @Boehringer]

#PRESS: We’re teaming up with @MiratiTx to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C selective inhibitor ➡ https://t.co/lvV1P75o4Y

[Darryl B McConnell @D_B_McConnell]

Exciting news on Boehringer collaborating with Mirati on KRAS. Combining our SOS1 inhibitor with Mirati's KRAS-G12C in the clinic. https://t.co/XjCncyuCLa

[Marco Hofmann @MarcoHHofmann]

@Real_Dr_Kessler @D_B_McConnell @castel_pau @RASopathiesnet @Noonan_Syndrome @noonansyndrome @NoonanSyndrome1 @NoonanNet @SyndromeNoonan @Noonan2015 @NoonanSyndroom NRAS and HRAS mutant cell lines are insensitive to SOS1 inhibition by BI-3406 in MONOTHERAPY.